All News
Future Big BiTEs (6.28.2024)
Dr. Jack Cush reviews the news, journal articles and regulatory announcements from the past week on RheumNow.com.
Read Article
New Treatments for Systemic Sclerosis
EurekAlert!
Autologous hematopoietic stem cell transplantation (aHSCT) for SSc has been proven the most effective treatment strategy with regard to overall and event free survival in selected patients.2 But a key limitation is its toxicity, and new treatment options are needed.
Read Article
Is Cannabis Safe? (6.7.2024)
Dr. Jack Cush reviews FDA approval, news and journal articles -- and it’s the week before EULAR 2024 in Vienna!!
Read Article
The Window of Opportunity (5.24.2024)
Dr. Jack Cush reviews the journal reports and news from the past week on RheumNow.com. This week: blockbuster drugs, opioids in rheumatology and nontreatment of inflammatory arthritis?
Read Article
EUSTAr study of 4431 systemic sclerosis (SSc) pts - anti-SSA antibodies are detected in 15% of SSc-patients and represent an independent risk factor for the presence of lung fibrosis (OR 1.24) & more severe lung involvement. #EULA2024 OP0013 https://t.co/NcxReWk83n https://t.co/FSMx22XiNo
Dr. John Cush RheumNow ( View Tweet)
Finnish study of 331 systemic sclerosis (SSc) pts found that SSc is the major cause of death in diffuse & limited SSc. Among 91 deaths, the 5 & 10 year survival was 88% and 80%. Most common cause death was SSc (n=35)& ILD (13). https://t.co/m30CoAdsMN https://t.co/Ms9LN7eAUK
Dr. John Cush RheumNow ( View Tweet)
EUSTAr study of 4431 systemic sclerosis (SSc) pts - anti-SSA antibodies are detected in 15% of SSc-patients and represent an independent risk factor for the presence of lung fibrosis (OR 1.24) & more severe lung involvement. #EULA2024 OP0013 https://t.co/oW6NBjIG7E https://t.co/toyvHxJlr9
Dr. John Cush RheumNow ( View Tweet)
Rituximab vs. Tocilizimab for Scleroderma: Which is Better?
Dr. Janet Pope discusses abstract OP0295 presented at Eular 2024 in Vienna, Austria.
https://t.co/70YF2wxwj5 https://t.co/8BHCafFs3u
Dr. John Cush RheumNow ( View Tweet)
New Treatments for Systemic Sclerosis
aHSCT for SSc has been proven the most effective treatment strategy with regard to overall and event free survival in selected patients.2 But a key limitation is its toxicity, and new treatment options are needed.
https://t.co/xUI0plrk42 https://t.co/DqGUhU6D1Z
Dr. John Cush RheumNow ( View Tweet)
#Scleroderma updated #EULAR2024
#recommendations @eular_org
SKIN
Are they good enough?
Great work by task force @EUSTAR_org
Do we alter initial Rx if v high mRSS?
Ex #MMF not much improvement on skin vs #RTX #Cyclo
Or combo Rx?
We need to improve #SoC
?CAR-T ? RCT
@RheumNow https://t.co/WhEzDdjVeu
Janet Pope Janetbirdope ( View Tweet)
#Scleroderma updated #EULAR2024
#recommendations @eular_org
Are they good enough?
Great work by task force @EUSTAR_org
#PAH my thoughts
Where does #sotaracept in #PAH fit in
Not mentioned
?#selexipag before #epoprostenol
For sure there is country variant
@RheumNow https://t.co/3dJ6eusSkU
Links:
Janet Pope Janetbirdope ( View Tweet)
Agree!
Liz Volkmann said it straight
Unsustainable RCTs in ILD trials in #scleroderma
Why
Can’t recruit
~same pool of early #dcSSc design RCT
UNETHICAL a to have a progressing #scleroderma-ILD Pt on failed background #MMF + placebo for 1 yr
🙏🏻 #EULAR2024 @RheumNow @eular_org https://t.co/29oFEazwmM
Janet Pope Janetbirdope ( View Tweet)
#EULAR2024 OP0295 Approriate patient stratification matters in trials. H2H RCT of Tocilizumab vs Rituximab in refractory #SSc-ILD (failed CyC), stratified based on RNA-seq of lungs biopsy showed improved efficacy in TCZ with low B-cell lineage expression signature @RheumNow https://t.co/7ME3Bd2PeM
Links:
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
#EULAR2024 OP0288 Patients with Scleroderma shouldn’t be excluded from Lung Transplantation because of a concern with post-surgery complications/long term complications. Data from Italy of N=13 pts showed 93% survival, improved disesase activity & FVC over 2 years @RheumNow https://t.co/zPFB1MFxdc
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
#EULAR2024 OP0256 Phase 2 RCT ReSScue data of fecal microbiota transplantation did not meet primary endpoint (bloating & diarrhoea) in scleroderma. How about impact on faecal incontinence symptoms? This improved throughout 20wks. Could be due improved stool consistency @RheumNow https://t.co/1t7d3M5S4Z
Links:
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
#SARD #ILD
Who to screen for #rheumatic #diseases
For
ILD
#ACR guidelines
Screening May also depend on ILD prevalence
Not sure if frequency of screening and how to screen
@jeffsparks #ORA24 @ORAexec https://t.co/BcyyYLKvr6
Links:
Janet Pope Janetbirdope ( View Tweet)
Review of the Scleroderma spectrum disorders (full-read) https://t.co/Z7cUrVeGRR https://t.co/VkYag0uZnX https://t.co/QK6bfcYBoF
Dr. John Cush RheumNow ( View Tweet)
Systemic sclerosis sine scleroderma in children is more aggressive than in adults. 18 juvenile vs 38 adults - ssJSSc more female (39% vs 89%), more digital pitting scars/ulcers (35 vs 10.5%), Pulm (50 vs 24) & CV (50 vs 3%); w/ more deaths https://t.co/l4f5bH1IX1 https://t.co/viQcD3tN9V
Dr. John Cush RheumNow ( View Tweet)
Untangling the relationship between smoking and systemic sclerosis: an analysis of the EUSTAR cohort
https://t.co/IB0cOAFnwl https://t.co/zpwm3JRKU4
Links:
Nelly ZIADE 🍀 Nellziade ( View Tweet)
Review article of Interstitial Lung Dz Assoc w/ Systemic Sclerosis. SSc-ILD prevalence ranges 25-95%; ILD is a main cause of morbidity and mortality, contributing to 35% of deaths https://t.co/8mMFbDu4gi https://t.co/nQ4GfNcMWt
Links:
Dr. John Cush RheumNow ( View Tweet)
